Survival and Toxicity of Hypofractionated Intensity Modulated Radiation Therapy in 4 Gy Fractions for Unresectable Stage III Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Survival and Toxicity of Hypofractionated Intensity Modulated Radiation Therapy in 4 Gy Fractions for Unresectable Stage III Non-Small Cell Lung Cancer

Published:2020-07 Issue:4 Volume:107 Page:710-719
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Kong Cheng,Zhu Xiangzhi,Shi Meiqi,Wang Li,Chen Cheng,Tao Hua,Jiang Ning,Yan Pengwei,Zhao Lijun,Song Xue,He Xia

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Radiation

Reference27 articles.

1. Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410;Curran;J Natl Cancer Inst,2011

2. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer;Furuse;J Clin Oncol,1999

3. Concurrent chemoradiotherapy in non-small cell lung cancer;O’Rourke;Cochrane Database Syst Rev,2010

4. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC;Antonia;N Engl J Med,2018

5. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer;Aupérin;J Clin Oncol,2010

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy with Helical TomoTherapy Versus Conventional Radiation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Receiving Concurrent Chemotherapy: A Multicenter, Randomized Phase 3 Trial;International Journal of Radiation Oncology*Biology*Physics;2024-10

2. Hypofractionation for Lung Tumors (Primary Malignant, Secondary Malignant);Hypofractionated and Stereotactic Radiation Therapy;2024

3. Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non–Small Cell Lung Cancer: Results of A Prospective Phase II Study (GASTO-1049);International Journal of Radiation Oncology*Biology*Physics;2023-10

4. Efficacy and toxicity of stereotactic body radiotherapy for un-resectable stage III non-small cell lung cancer patients unfit for concurrent chemoradiation therapy: a retrospective study;Radiation Oncology;2023-08-24

5. A pilot trial of consolidation bevacizumab after hypo‐fractionated concurrent chemoradiotherapy in patients with unresectable locally advanced non‐squamous non‐small‐cell lung cancer;Cancer Medicine;2023-08-03